31results about How to "No increase in toxicity" patented technology

The invention relates to a sterilizing composition containing benzothiostrobin and epoxiconazole. The sterilizing composition comprises an active component and an auxiliary component of a pesticide preparation, and particularly the active component consists of benzothiostrobin and epoxiconazole in a weight ratio of 1: (0.1-16). According to the sterilizing composition provided by the invention, benzothiostrobin and epoxiconazole are compounded in a special ratio, so that a very remarkable synergistic effect is achieved. A plenty of experiments verify that the toxicity of the compounded sterilizing composition is not increased for mammals. In addition, the applicant further discovers that the compounding effect of benzothiostrobin and epoxiconazole can be further promoted by adopting a special wetting dispersing agent, so that benzothiostrobin and epoxiconazole exert the synergistic effect to the maximum extent.

The invention relates to a sterilizing composite containing metconazole and trifloxystrobin. The sterilizing composite containing metconazole and trifloxystrobin comprises an active component and an auxiliary component of a pesticide preparation, wherein the active component comprises metconazole and trifloxystrobin according to the weight ratio of 1:0.03-30, and the active component accounts for no more than 85% of the weight content of the sterilizing composite. In the sterilizing composite, the metconazole and the trifloxystrobin with different mechanisms of action are compounded, and have an obvious synergistic effect. The sterilizing composite has the advantages that the control effect of the sterilizing composite is obvious, the resistance is lowered and delayed, and the toxicity (on the mammal) is not enhanced. In addition, the sterilizing composite provided by the invention has the advantages of small dosage, low cost of the composite and low environmental pollution.

The invention relates to a denatured protein powder and a brain protein hydrolyzate prepared from the same. The total nitrogen content of the denatured protein powder is more than 120 mg / g; and the denatured protein powder is prepared by adding fresh lysozyme into a pig brain, homogenating, heating, and defatting with acetone. The denatured protein powder, as a raw material, is used for preparingthe brain protein hydrolyzate; the contents of amino acids in the prepared brain protein hydrolyzate meet national standards of brain protein hydrolyzate injections; and the content of small moleculepeptides with the molecular weight of less than 10000 Da is 25-35% of the brain protein hydrolyzate. The preparation method of the brain protein hydrolyzate mainly comprises the following steps: pre-treating, homogenizing, defatting with the acetone, performing dual enzymatic hydrolysis, centrifugating, refining by column chromatography, and performing ultrafiltration treatment. The invention discloses key technical points for controlling the total nitrogen index of the protein powder and the content of the small molecule peptides for the first time; the obtained brain protein hydrolyzate is a biologically active substance which is really extracted from the pig brain, without adding active components artificially, thus ensuring the efficacy and the safety of the brain protein hydrolyzate;and animal pharmacodynamic experiments show that the brain protein hydrolyzate is more effective than conventional products.

The invention relates to a pharmaceutical composition of Vinflunine, which comprises Vinflunine as the active constituent, pharmaceutically acceptable salts and cyclodextrin, wherein each 1 part of Vinflunine and its pharmaceutically acceptable salt are mixed with a maximum of 0. 5-100 parts by weight ratio of cyclodextrin, and freeze dried injection is prepared. The invention also relates to theprocess for preparing the composition, and its use in preparing non-stomach administering pharmaceutical products for the treatment of cancer.

The invention relates to a sterilization composition containing benzothiostrobin and epoxiconazole. The sterilization composition containing benzothiostrobin and epoxiconazole comprises active ingredients and auxiliary components of pesticide preparations, wherein the active ingredients are composed of benzothiostrobin and epoxiconazole in weigh ratio of 1: (0.1-16). The sterilization composition containing benzothiostrobin and epoxiconazole has a very remarkable synergistic effect by compounding benzothiostrobin and epoxiconazole according to a special proportion; and lots of experiments prove that after benzothiostrobin and epoxiconazole are compounded, the toxicity to mammals is not increased. In addition, the applicant further finds that the compounding effect of benzothiostrobin and epoxiconazole can be further promoted by adopting a specific dispersion wetting agent with the help of the sterilization composition, so that benzothiostrobin and epoxiconazole give play to the synergistic effect to the maximum extent.

The invention relates to a ternary compound bactericidal composition and application thereof. The ternary compound bactericidal composition is composed of an active ingredient and a pesticide preparation auxiliary component, wherein the active ingredient is formed by compounding pyraclostrobin, metconazole and carbendazim together in a weight ratio of (0.05-1): (0.05-1.5): 1; and the pesticide preparation auxiliary component comprises compound sodium nitrophenolate accounting for 0.05-2% of the composition in mass percent. The ternary compound bactericidal composition is formed by compounding pyraclostrobin, metconazole and carbendazim together in a special ratio, thereby achieving very obvious synergistic interaction effect; and provided by lots of experiments, after compounding, toxicity on the mammal is not increased. Besides, the applicant further finds out the compounding effect of pyraclostrobin, metconazole and carbendazim can be further promoted in the special form of wetting dispersant and wetting dispersing agent according to the invention; and therefore, the synergistic effect of the three ingredients is developed to an utmost extent.

The present invention provides a new drug treatment composition for treating hyperlipidemia, which is charactered in that it contains an effective volume of Acipimox and Simvastatin, and it has a weight ratio of (10 ~ 80): 1, a preferable weight ratio of (10 ~ 40): 1, and further preferable weight ratio of 15:1. Its lipid-lowering effect is superior to the same dose of signal prescription, which indicates the two drugs have synergistic effects, and at the same time have no obvious toxicity.